


# Big Bear Pharma Announces Approval of Six Anti-Cancer Targeted Drugs in Laos

*Targeted cancer drug approved for lung cancer and leukemia.*

VIENTIANE, LAO PDR, May 3, 2023 /EINPresswire.com/ -- Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapies for cancer, announced today that it has received approval from the Ministry of Health of Laos for six anti-cancer targeted drugs.



Targeted cancer drug approved for lung cancer and leukemia including  
The inhibitor of MEK drug

“

We are thrilled to receive the approval of our six anti-cancer targeted drugs in Laos, which demonstrates our commitment to delivering cutting-edge therapies to patients in need”

*Nipaporn Khunkaw, CEO of Big Bear Pharma*

The inhibitor of ALK and ROS1 drug  
The inhibitor of a mutation that leads to the exon 14 skipping of the MET gene drug  
The inhibitor of FLT3 drug  
The inhibitor of Janus kinase drug

The approval of these drugs marks a significant milestone for Big Bear Pharma and its mission to bring innovative and effective treatments to patients with cancer in Laos and beyond. The company plans to launch the drugs in the local market in the coming months and to expand its presence in the Southeast Asian region.

“We are thrilled to receive the approval of our six anti-cancer targeted drugs in Laos, which demonstrates our commitment to delivering cutting-edge therapies to patients in need,” said Nipaporn Khunkaw, CEO of Big Bear Pharma. “We are grateful to the Ministry of Health of Laos for their support and collaboration throughout the regulatory process. We look forward to working with them and other stakeholders to ensure the accessibility and affordability of our drugs for the people of Laos.”

## About Big Bear Pharma

Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs. Visit: [www.BigBearpharma.com](http://www.BigBearpharma.com) to know more information.

## Forward-Looking Statements

To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.

Spencer

RxLibra pharmaceutical Sole Co.,Ltd

+856 20 54 177 436

[info@rxlibra.com](mailto:info@rxlibra.com)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/631481254>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.